Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'

Jonathan W. Mant

doi:10.1160/TH08-06-0344

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2008; 100(01): 14-15
DOI: 10.1160/TH08-06-0344

Pro / Contra Articles

Schattauer GmbH

Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'

Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation

Autoren

Jonathan W. Mant

Abstract

Volltext

Referenzen

References
1 Fuster V, Ryden LE, Cannom DS. et al. ACC/AHA/ ESC 2006 Guidelines for the management of patients with atrial fibrillation - executive summary. Circulation 2006; 114: 700-752.
2 bNational Collaborating Centre for Chronic Conditions. Atrial fibrillation: the management of atrial fibrillation. NICE Clinical Guideline 36. National Institute for Health and Clinical Excellence. London: 2006
3 Wang TJ, Massaro JM, Levy D. et al. a risk score for predicting stroke or death in individuals with new onset atrial fibrillation in the community: the Framingham Heart Study. J Am Med Assoc 2003; 290: 1049-1056.
4 Hylek EM, D’Antonio J, Evans-Molina C. et al. Translating the results of randomised trials into clinical practice: the challenge of warfarin candidacy among hospitalised elderly patients with atrial fibrillation. Stroke 2006; 37: 1075-1080.
5 Mant J, Hobbs FDR, Fletcher K. et al. on behalf of the BAFTA Investigators Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA ): a randomised controlled trial. Lancet 2007; 370: 493-503.
6 Van Walraven C, Hart RG, Singer DE. et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. J Am Med Assoc 2002; 288: 2441-2448.
7 The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
8 Mant J, Hobbs FDR, Fletcher K. et al. on behalf of the BAFTA Investigators and the Midlands Research Practices Network Warfarin versus aspirin for stroke prevention (BAFTA ). Lancet 2007; 370: 1606-1607.
9 Hylek EM, Evans-Molina C, Shea C. et al. Major haemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
10 Kalra L, Yu G, Perez I. et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. Br Med J 2000; 320: 1236-1239.
11 Hughes M, Lip GY. Guideline Development Group National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care National Institute for Health and Clinical Excellence Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
12 Lip GY. Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. Br Med J 2008; 336: 614-615.